Trial reportNature2022
Combination anti-HIV antibodies provide sustained virological suppression.
Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06908083 (A Study to Evaluate Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART), which is not on this map. Cited by 116 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed, 2 pooled it
11.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06908083 phase1enrolling by invitationnot on this mapstarted 2025, after this paper: background citation
A Study to Evaluate Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.Nature communications · 2025Pooled it
- Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.Nature communications · 2026Trial
- VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results.The Journal of infectious diseases · 2025Trial
- Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data.Journal of the International AIDS Society · 2025Trial
- Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.Nature medicine · 2024Trial
- Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.The lancet. HIV · 2024Trial
- Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.Nature medicine · 2023Trial
- Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.Science translational medicine · 2023Trial
- Could AAV-vectored delivery of broadly neutralizing antibodies (bNAbs) reduce virologic failure in children diagnosed with perinatal HIV?Human vaccines & immunotherapeutics · 2026Review
- Article
- Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials.Nature microbiology · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- HIV-1 Env Heterogeneity: Cleavage, Trafficking, and Antigenic Consequences for Virions and Infected Cells.Viruses · 2026Review
- Haplotype and diversity signatures of ultra-soft selective sweeps in HIV-1.bioRxiv : the preprint server for biology · 2026Article
- Article
- Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.Science (New York, N.Y.) · 2026Article
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- Immune activation during broadly neutralizing antibody-mediated HIV suppression prior to post-intervention control.bioRxiv : the preprint server for biology · 2026Article
- Review
56 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 7 institutions in 2 countries.
Michael C Sneller *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Jana Blazkova *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6000-202X
J Shawn JustementLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Victoria ShiLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Brooke D KennedyLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Kathleen GittensCritical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, USA.
Jekaterina TolstenkoLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Genevieve McCormackLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-9486-0065
Emily J WhiteheadLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Rachel F SchneckLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Michael A ProschanBiostatistics Research Branch, NIAID, NIH, Bethesda, MD, USA.
Erika BenkoMaple Leaf Medical Clinic, Toronto, Ontario, Canada.
Colin KovacsMaple Leaf Medical Clinic, Toronto, Ontario, Canada.
Cihan OguzNIAID Collaborative Bioinformatics Resource, NIAID, NIH, Bethesda, MD, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1727-8693
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0592-8564
Anthony S FauciLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Susan Moir *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Tae-Wook Chun *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. twchun@nih.gov.ORCID http://orcid.org/0000-0001-5153-7340
National Institutes of Health · USMaple Leaf Medical Clinic · CABeth Israel Deaconess Medical Center · USFrederick National Laboratory for Cancer Research · USHoward Hughes Medical Institute · USNational Institutes of Health Clinical Center · USRockefeller University · US
Funding
Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1MStuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MRole of Viral Reservoirs in the Pathogenesis of HIV DiseaseZIAAI000851 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHUN, TAE-WOOK · 2009 to 2025
$29.3MRole of B Lymphocytes In HIV Infection And PathogenesisZIAAI000825 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MOIR, SUSAN · 2009 to 2025
$24.5MIntramural NIH HHS ZIA AI000851
Abstract
Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV)
Indexed as
Antibodies, NeutralizingAnti-HIV AgentsHIV-1HIV AntibodiesHIV InfectionsAntibodies, MonoclonalBroadly Neutralizing AntibodiesDouble-Blind MethodHumansViral LoadViremiaAntibodies, MonoclonalAntibodies, NeutralizingAnti-HIV AgentsBroadly Neutralizing AntibodiesHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT06908083ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.